Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;14(4):286-293.
doi: 10.1097/COH.0000000000000550.

Coevolution of HIV-1 and broadly neutralizing antibodies

Nicole A Doria-Rose  1 , Elise Landais  2
Affiliations
Review

Coevolution of HIV-1 and broadly neutralizing antibodies

Nicole A Doria-Rose et al. Curr Opin HIV AIDS. 2019 Jul.

Abstract

Purpose of review: Exploring the molecular details of the coevolution of HIV-1 Envelope with broadly neutralizing antibodies (bNAbs) in infected individuals over time provides insights for vaccine design. Since mid-2017, the number of individuals described in such publications has nearly tripled. New publications have extended such studies to new epitopes on Env and provided more detail on previously known sites.

Recent findings: Studies of two donors - one of them an infant, the other with three lineages targeting the same site - has deepened our understanding of V3-glycan-directed lineages. A V2-apex-directed lineage showed remarkable similarity to a lineage from a previously described donor, revealing general principles for this class of bNAbs. Understanding development of CD4 binding site antibodies has been enriched by the study of a VRC01-class lineage. Finally, the membrane-proximal external region is a new addition to the set of epitopes studied in this manner, with early development events explored in a study of three lineages from a single donor.

Summary: These studies provide templates for immunogen design to elicit bNAbs against a widened set of epitopes, generating new directions in the quest for an HIV vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Sites of vulnerability on the HIV-1 Env trimer. Model shows Env trimer as determined by cryo-electron microscopy and X-ray crystallography. Epitopes of known bNAbs are shown with their footprints color-coded. Viral membrane is shown in light gray. bNAbs from lineages described in the text are color-coded by epitope. N-terminal and C-terminal portions of MPER are distinguished by color. The CAP256-VRC26.09 bNAb (cyan) is shown for scale. bNAbs, broadly neutralizing antibodies; MPER, membrane-proximal external region. Source: Image adapted from Refs. [11-14].
See this image and copyright information in PMC

References

    1. Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol 2018; 19:1179–1188. - PMC - PubMed
    1. Pegu A, Hessell AJ, Mascola JR, Haigwood NL. Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev 2017; 275:296–312. - PMC - PubMed
    1. Burton DR, Ahmed R, Barouch DH, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012; 12:396–407. - PMC - PubMed
    1. Andrabi R, Voss JE, Liang CH, et al. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 2015; 43:959–973. - PMC - PubMed
    1. Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340:711–716. - PMC - PubMed

Publication types